Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • beameup_999 beameup_999 Oct 20, 2011 10:13 PM Flag

    More Good News

    Canaccord Genuity Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); DIFICID Uptake Appears Steady

    More News related to OPTR
    Canaccord Genuity Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); DIFICID Uptake Appears Steady
    DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
    Optimer Pharmaceuticals' DIFICID Featured in Presentations at 49th Annual Meeting of IDSA
    Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
    Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    More News related to OPTR
    October 20, 2011 8:42 AM EDT

    Canaccord Genuity maintains a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $20.00.

    Canaccord analyst, George Farmer, said, "Positive script trends over the first three months since DIFICID launch for treatment of C. diff. infection (CDI) support our view of its strong potential...In our view, DIFICID approval as a new CDI treatment option and steady formulary adoption should enable grab of Vancocin share. However, comparison of DIFICID vs. Vancocin script trend shows relatively flat Vancocin script numbers since Dificid launch, per WK (Figure 2). This may reflect the majority of DIFICID application post-Vancocin use. Upside could come from increased first-line uptake as doctors gain more clinical experience with this drug.

    SortNewest  |  Oldest  |  Most Replied Expand all replies